AYTU: Aytu BioPharma, Inc. Stock

by  •  • Comments Off on AYTU: Aytu BioPharma, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 16.48
Enterprise Value ($M) 12.96
Book Value ($M) 32.85
Book Value / Share 5.90
Price / Book 0.50
NCAV ($M) -27.02
NCAV / Share -4.85
Price / NCAV -0.61

Profitability (mra)
Return on Invested Capital (ROIC) -0.35
Return on Assets (ROA) -0.12
Return on Equity (ROE) -0.44

Liquidity (mrq)
Quick Ratio 0.91
Current Ratio 1.11

Balance Sheet (mrq) ($M)
Current Assets 71.37
Assets 131.25
Liabilities 98.40
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Stonepine Capital Management, LLC 9.99 0.29
06-16 13D/A Nantahala Capital Management, LLC 19.70 300.16

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-10-12 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2023-05-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-02 1,635 7,345 22.26
2024-05-01 2,217 7,931 27.95
2024-04-30 1,175 22 5,340.91
2024-04-29 2,649 324 817.59

(click for more detail)

Similar Companies
ATXI – Avenue Therapeutics, Inc. AVTX – Avalo Therapeutics, Inc.
AWH – Aspira Women's Health Inc. BCDA – BioCardia, Inc.
BCLI – Brainstorm Cell Therapeutics Inc.


Financial data and stock pages provided by
Fintel.io